Autoimmune retinopathy medical therapy

Revision as of 14:51, 17 July 2022 by Hassan M (talk | contribs) (→‎Medical Therapy: Added content)
Jump to navigation Jump to search

Autoimmune retinopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune retinopathy from other Diseases

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune retinopathy medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune retinopathy medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune retinopathy medical therapy

CDC on Autoimmune retinopathy medical therapy

Autoimmune retinopathy medical therapy in the news

Blogs on Autoimmune retinopathy medical therapy

Directions to Hospitals Treating Autoimmune retinopathy

Risk calculators and risk factors for Autoimmune retinopathy medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S

Overview

Medical Therapy

Currently no standard treatment protocol exists for autoimmune retinopathy (AIR). However, various treatment options have been described in the literature, and they are as follows:

Systemic and/or topical corticosteroids

Immunosuppression through systemic and/or topical (intravitreal/sub-tenon/depot) corticosteroids.  For all cases of AIR initiate steroids (local or systemic) and/or with antimetabolites/T-cell inhibitors, as the first or second-line treatment respectively, after systemic management of the underlying autoimmune disease.

Initiate a short-term treatment trial with intravitreal or sub-tenon triamcinolone (40-80 mg, two injections over a span of 8 months), before starting systemic steroids (60-80 mg oral prednisone daily); this aids in both confirmation of the diagnosis as well as avoidance of adverse effects of the treatment.

Immunomodulators

Immunomodulators like cyclosporine (calcineurin inhibitor which prevents IL-2 transcription), infliximab (anti-TNFα antibody), mycophenolate mofetil (IMP dehydrogenase inhibitor, preventing purine synthesis), azathioprine (purine antimetabolite).

Biological agents

Biological agents such as monoclonal antibodies like rituximab (anti-CD20 antibody), alemtuzumab (anti-CD52 antibody), ipilimumab (antagonist antibody against cytotoxic T-lymphocyte antigen-4), tocilizumab (anti-IL-6 receptor antibody), sarilumab (anti-IL-6 receptor antibody)

Intravenous immunoglobulin (IVIG), and Plasmapheresis

Intravenous immunoglobulin (IVIG), plasmapheresis are effective if given before the onset of irreversible neuronal degeneration.

IVIG has several mechanisms of action like, neutralization of autoantibodies, binding of complement components, inhibition of dendritic cells maturation, modulation of intercellular adhesion, and contribution of IgG4.

Antioxidants

Antioxidant vitamins like lutein, Vitamin C, Vitamin E, and beta carotene (in non-smokers) also play a role in stabilizing retinal degeneration and disease course.


To monitor the response to management, follow-up testing with ERG, visual field testing, visual acuity, OCT, and colour vision testing may be conducted every 3 to 6 months.

References


Template:WH Template:WS